NIH Partnership To Pick COVID-19 Therapeutics For Clinical Trials; Results Anticipated By Summer
NIH public-private partnership with FDA, CDC, BARDA and 16 biopharma companies to rank most promising therapeutics and vaccines to advance into clinical trials; candidates expected to be tested simultaneously under master protocol.
You may also be interested in...
Efforts to find new uses for old drugs in COVID-19 patients are gathering pace.
The expectation of a big second quarter sales decline proved true, but the situation is improving. Meanwhile, Merck & Co. is advancing two vaccines and an antiviral against the novel coronavirus.
Three host-targeted immune modulators, three anticoagulants, and three to six neutralizing antibodies are to be tested in ACTIV clinical trials, FNIH's David Wholley tells DIA meeting.